- About Us
- Nano-Social Network
- Nano Consulting
- My Account
September 7th, 2007
NanoCor Therapeutics has landed a $3.75 million investment from medical device firm Medtronic, The News & Observer reported Friday.
The company is using technology at the University of North Carolina at Chapel Hill to use a genetically engineered virus as a means of drug delivery. Its initial target is people suffering from congestive heart failure. The company calls its technology platform "biological nanoparticle."
|Related News Press|
Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017
Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017
ATTOPSEMI Technology Joins FDXcelerator Program to Deliver Advanced Non-Volatile Memory IP to GLOBALFOUNDRIES 22 FDX® Technology Platform: Leading-edge I-fuse™ brings higher reliability, smaller cell size and ease of programmability for consumer, automotive, and IoT applications March 27th, 2017
Leti and HORIBA Scientific to Host Webinar on Ultrafast Characterization Tool: Plasma Profiling Time-of-Flight Mass Spectrometer Tool Cuts Optimization Time In Layer Deposition and Fabrication of Wide Range of Applications March 27th, 2017